To include your compound in the COVID-19 Resource Center, submit it here.

Somnus compound meets Phase II insomnia endpoint

Somnus Therapeutics Inc. (Bedminster, N.J.) said all three doses of oral SKP-1041 given before

Read the full 143 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE